Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-058352
Filing Date
2025-04-25
Accepted
2025-04-25 08:30:10
Documents
18
Period of Report
2025-06-13

Document Format Files

Seq Description Document Type Size
1 DEF 14A acrv-20250424.htm   iXBRL DEF 14A 768181
2 GRAPHIC img244011982_0.jpg GRAPHIC 38597
3 GRAPHIC img244011982_1.jpg GRAPHIC 17219
4 GRAPHIC img244011982_2.jpg GRAPHIC 38597
5 GRAPHIC img244011982_3.jpg GRAPHIC 8094
6 GRAPHIC img244011982_4.jpg GRAPHIC 1382549
7 GRAPHIC img244011982_5.jpg GRAPHIC 415396
  Complete submission text file 0000950170-25-058352.txt   5381248

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT acrv-20250424.xsd EX-101.SCH 16001
20 EXTRACTED XBRL INSTANCE DOCUMENT acrv-20250424_htm.xml XML 57724
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

EIN.: 825125532 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41551 | Film No.: 25870114
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)